GlassScriptPhysician profile
Marshall G Baca
NPI 1376520601
$13,359.27
in general payments reported to CMS, 2019-2025
9 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,783 · 2020: $3,741 · 2021: $228 · 2022: $574 · 2023: $1,651 · 2024: $2,983 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,561 · Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,560.95 |
| Food and Beverage | $1,473.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $4,555.06 | 2019-2024 | Bone Anchors With Arthroscopic Delivery System, Q-Fix, Microraptor |
| Stryker Corporation | $3,817.95 | 2019-2025 | Mako, Actishield, Gamma |
| Rattan and Associates | $2,558.73 | 2020-2023 | |
| Goode Surgical INC | $2,305.00 | 2020 | |
| Olympus America INC. | $40.00 | 2025 | Olympus, Hd Camera Head |
| Davol INC. | $26.64 | 2022 | |
| Depuy Synthes Sales INC. | $21.64 | 2021 | |
| Arthrex, INC. | $18.00 | 2023 | |
| Ferring Pharmaceuticals INC. | $16.25 | 2023 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Baca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.